2010
DOI: 10.1186/1471-2407-10-480
View full text
|
|
Share

Abstract: BackgroundIn the era of cytokines, patients with brain metastases (BM) from renal cell carcinoma had a significantly shorter survival than patients without. Targeted agents (TA) have improved the outcome of patients with metastatic renal cell carcinoma (mRCC) however, their impact on patients with BM is less clear. The aim of this analysis was to compare the outcome of patients with and without BM in the era of targeted agents.MethodsData from 114 consecutive patients who had access to targeted agent were anal…

Expand abstract

Search citation statements

Order By: Relevance

Paper Sections

0
0
0
0
0

Citation Types

2
25
0

Publication Types

Select...

Relationship

0
0

Authors

Journals